Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1)
•Immune escape of SARS-CoV-2 variants spurred the development of bivalent vaccines.•We compared antibody response following monovalent or bivalent mRNA vaccination.•While IgG responses are similar, IgA responses are lower post bivalent booster.•IgA are particularly lower in bivalent-booster-vaccinee...
Saved in:
Published in | International journal of infectious diseases Vol. 146; p. 107147 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Canada
Elsevier Ltd
01.09.2024
Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 1201-9712 1878-3511 1878-3511 |
DOI | 10.1016/j.ijid.2024.107147 |
Cover
Abstract | •Immune escape of SARS-CoV-2 variants spurred the development of bivalent vaccines.•We compared antibody response following monovalent or bivalent mRNA vaccination.•While IgG responses are similar, IgA responses are lower post bivalent booster.•IgA are particularly lower in bivalent-booster-vaccinees with prior infection.•IgA are skewed towards WT in bivalent-booster-vaccinees with prior infection.
The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent vaccines may improve antibody responses against new variants.
A total of 107 participants, who had three COVID-19 WT mRNA vaccine doses, were recruited, and given either a monovalent (WT) or a bivalent mRNA vaccination (Pfizer/BioNTech Bivalent (WT and BA.4/BA.5) or Moderna Bivalent (WT and BA.1). Blood samples were taken before booster and at 28 days post-booster.
We found significantly lower fold change in serum binding IgA responses against BA.1, BA.5 and EG.5.1 spike in the bivalent booster group, compared with the monovalent (WT) booster group, following vaccination. However, this was only observed in individuals with prior infection. The relative fold change in serum binding IgA response was more skewed towards WT over variant (BA.1, BA.5 or EG.5.1) spike in previously infected bivalent-booster-vaccinees, as compared with previously infected monovalent-(WT)-booster-vaccinees.
The findings suggest imprinting of antibody responses that is shaped by the first vaccination (WT spike). Previous infection also affects the boosting effect of follow-up vaccination. Studies are needed to understand how to induce a robust and long-lasting IgA immunity for protection against COVID-19 infection. |
---|---|
AbstractList | Objectives: The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent vaccines may improve antibody responses against new variants. Methods: A total of 107 participants, who had three COVID-19 WT mRNA vaccine doses, were recruited, and given either a monovalent (WT) or a bivalent mRNA vaccination (Pfizer/BioNTech Bivalent (WT and BA.4/BA.5) or Moderna Bivalent (WT and BA.1). Blood samples were taken before booster and at 28 days post-booster. Results: We found significantly lower fold change in serum binding IgA responses against BA.1, BA.5 and EG.5.1 spike in the bivalent booster group, compared with the monovalent (WT) booster group, following vaccination. However, this was only observed in individuals with prior infection. The relative fold change in serum binding IgA response was more skewed towards WT over variant (BA.1, BA.5 or EG.5.1) spike in previously infected bivalent-booster-vaccinees, as compared with previously infected monovalent-(WT)-booster-vaccinees. Conclusion: The findings suggest imprinting of antibody responses that is shaped by the first vaccination (WT spike). Previous infection also affects the boosting effect of follow-up vaccination. Studies are needed to understand how to induce a robust and long-lasting IgA immunity for protection against COVID-19 infection. •Immune escape of SARS-CoV-2 variants spurred the development of bivalent vaccines.•We compared antibody response following monovalent or bivalent mRNA vaccination.•While IgG responses are similar, IgA responses are lower post bivalent booster.•IgA are particularly lower in bivalent-booster-vaccinees with prior infection.•IgA are skewed towards WT in bivalent-booster-vaccinees with prior infection. The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent vaccines may improve antibody responses against new variants. A total of 107 participants, who had three COVID-19 WT mRNA vaccine doses, were recruited, and given either a monovalent (WT) or a bivalent mRNA vaccination (Pfizer/BioNTech Bivalent (WT and BA.4/BA.5) or Moderna Bivalent (WT and BA.1). Blood samples were taken before booster and at 28 days post-booster. We found significantly lower fold change in serum binding IgA responses against BA.1, BA.5 and EG.5.1 spike in the bivalent booster group, compared with the monovalent (WT) booster group, following vaccination. However, this was only observed in individuals with prior infection. The relative fold change in serum binding IgA response was more skewed towards WT over variant (BA.1, BA.5 or EG.5.1) spike in previously infected bivalent-booster-vaccinees, as compared with previously infected monovalent-(WT)-booster-vaccinees. The findings suggest imprinting of antibody responses that is shaped by the first vaccination (WT spike). Previous infection also affects the boosting effect of follow-up vaccination. Studies are needed to understand how to induce a robust and long-lasting IgA immunity for protection against COVID-19 infection. The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent vaccines may improve antibody responses against new variants.OBJECTIVESThe emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent vaccines may improve antibody responses against new variants.A total of 107 participants, who had three COVID-19 WT mRNA vaccine doses, were recruited, and given either a monovalent (WT) or a bivalent mRNA vaccination (Pfizer/BioNTech Bivalent (WT and BA.4/BA.5) or Moderna Bivalent (WT and BA.1). Blood samples were taken before booster and at 28 days post-booster.METHODSA total of 107 participants, who had three COVID-19 WT mRNA vaccine doses, were recruited, and given either a monovalent (WT) or a bivalent mRNA vaccination (Pfizer/BioNTech Bivalent (WT and BA.4/BA.5) or Moderna Bivalent (WT and BA.1). Blood samples were taken before booster and at 28 days post-booster.We found significantly lower fold change in serum binding IgA responses against BA.1, BA.5 and EG.5.1 spike in the bivalent booster group, compared with the monovalent (WT) booster group, following vaccination. However, this was only observed in individuals with prior infection. The relative fold change in serum binding IgA response was more skewed towards WT over variant (BA.1, BA.5 or EG.5.1) spike in previously infected bivalent-booster-vaccinees, as compared with previously infected monovalent-(WT)-booster-vaccinees.RESULTSWe found significantly lower fold change in serum binding IgA responses against BA.1, BA.5 and EG.5.1 spike in the bivalent booster group, compared with the monovalent (WT) booster group, following vaccination. However, this was only observed in individuals with prior infection. The relative fold change in serum binding IgA response was more skewed towards WT over variant (BA.1, BA.5 or EG.5.1) spike in previously infected bivalent-booster-vaccinees, as compared with previously infected monovalent-(WT)-booster-vaccinees.The findings suggest imprinting of antibody responses that is shaped by the first vaccination (WT spike). Previous infection also affects the boosting effect of follow-up vaccination. Studies are needed to understand how to induce a robust and long-lasting IgA immunity for protection against COVID-19 infection.CONCLUSIONThe findings suggest imprinting of antibody responses that is shaped by the first vaccination (WT spike). Previous infection also affects the boosting effect of follow-up vaccination. Studies are needed to understand how to induce a robust and long-lasting IgA immunity for protection against COVID-19 infection. The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent vaccines may improve antibody responses against new variants. A total of 107 participants, who had three COVID-19 WT mRNA vaccine doses, were recruited, and given either a monovalent (WT) or a bivalent mRNA vaccination (Pfizer/BioNTech Bivalent (WT and BA.4/BA.5) or Moderna Bivalent (WT and BA.1). Blood samples were taken before booster and at 28 days post-booster. We found significantly lower fold change in serum binding IgA responses against BA.1, BA.5 and EG.5.1 spike in the bivalent booster group, compared with the monovalent (WT) booster group, following vaccination. However, this was only observed in individuals with prior infection. The relative fold change in serum binding IgA response was more skewed towards WT over variant (BA.1, BA.5 or EG.5.1) spike in previously infected bivalent-booster-vaccinees, as compared with previously infected monovalent-(WT)-booster-vaccinees. The findings suggest imprinting of antibody responses that is shaped by the first vaccination (WT spike). Previous infection also affects the boosting effect of follow-up vaccination. Studies are needed to understand how to induce a robust and long-lasting IgA immunity for protection against COVID-19 infection. |
ArticleNumber | 107147 |
Author | Loh, Chiew Yee Lye, David C. Fong, Siew‐Wai Ng, Lisa F.P. Hor, Pei Xiang Ngoh, Eve Zi Xian Salleh, Siti Nazihah Mohd Young, Barnaby Edward Goh, Yun Shan Wang, Bei Chia, Po Ying Renia, Laurent Wang, Cheng-I Lee, I. Russel Lee, Raphael Tze Chuen Poh, Xuan Ying Leo, Yee‐Sin Tay, Matthew Zirui Rao, Suma Maurer-Stroh, Sebastian |
AuthorAffiliation | ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore |
AuthorAffiliation_xml | – name: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore |
Author_xml | – sequence: 1 givenname: Yun Shan surname: Goh fullname: Goh, Yun Shan organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore – sequence: 2 givenname: Siew‐Wai surname: Fong fullname: Fong, Siew‐Wai organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore – sequence: 3 givenname: Pei Xiang surname: Hor fullname: Hor, Pei Xiang organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore – sequence: 4 givenname: Chiew Yee surname: Loh fullname: Loh, Chiew Yee organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore – sequence: 5 givenname: Matthew Zirui orcidid: 0000-0002-1763-913X surname: Tay fullname: Tay, Matthew Zirui organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore – sequence: 6 givenname: Bei orcidid: 0000-0002-3112-7341 surname: Wang fullname: Wang, Bei organization: Singapore Immunology Network, ASTAR, Singapore, Singapore – sequence: 7 givenname: Siti Nazihah Mohd orcidid: 0000-0002-6110-7472 surname: Salleh fullname: Salleh, Siti Nazihah Mohd organization: Singapore Immunology Network, ASTAR, Singapore, Singapore – sequence: 8 givenname: Eve Zi Xian orcidid: 0000-0001-5407-0280 surname: Ngoh fullname: Ngoh, Eve Zi Xian organization: Singapore Immunology Network, ASTAR, Singapore, Singapore – sequence: 9 givenname: Raphael Tze Chuen surname: Lee fullname: Lee, Raphael Tze Chuen organization: Bioinformatics Institute, ASTAR, Singapore, Singapore – sequence: 10 givenname: Xuan Ying orcidid: 0000-0001-6077-0515 surname: Poh fullname: Poh, Xuan Ying organization: National Centre for Infectious Diseases, Singapore, Singapore – sequence: 11 givenname: I. Russel surname: Lee fullname: Lee, I. Russel organization: National Centre for Infectious Diseases, Singapore, Singapore – sequence: 12 givenname: Suma surname: Rao fullname: Rao, Suma organization: National Centre for Infectious Diseases, Singapore, Singapore – sequence: 13 givenname: Po Ying orcidid: 0000-0002-8797-9527 surname: Chia fullname: Chia, Po Ying organization: National Centre for Infectious Diseases, Singapore, Singapore – sequence: 14 givenname: Sebastian orcidid: 0000-0003-0813-9640 surname: Maurer-Stroh fullname: Maurer-Stroh, Sebastian organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore – sequence: 15 givenname: Cheng-I surname: Wang fullname: Wang, Cheng-I organization: Singapore Immunology Network, ASTAR, Singapore, Singapore – sequence: 16 givenname: Yee‐Sin orcidid: 0000-0003-4978-5825 surname: Leo fullname: Leo, Yee‐Sin organization: National Centre for Infectious Diseases, Singapore, Singapore – sequence: 17 givenname: David C. surname: Lye fullname: Lye, David C. organization: National Centre for Infectious Diseases, Singapore, Singapore – sequence: 18 givenname: Barnaby Edward surname: Young fullname: Young, Barnaby Edward organization: National Centre for Infectious Diseases, Singapore, Singapore – sequence: 19 givenname: Lisa F.P. surname: Ng fullname: Ng, Lisa F.P. organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore – sequence: 20 givenname: Laurent orcidid: 0000-0003-0349-1557 surname: Renia fullname: Renia, Laurent email: renia_laurent@idlabs.a-star.edu.sg organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38945433$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkUtvEzEUhUeoiD7gD7BAXpZFUj_mZcQmVDwiVSChIpbWtX0ncph4gj0JypJ_zg1TisQC2MzYV-d8ts85L07iELEongo-F1zUV-t5WAc_l1yWNGhE2TwozkTbtDNVCXFCa8nFTDdCnhbnOa8552Vdt4-KU9XqsiqVOiu-LzfbFOIY4ooNHVuuFixh3g4xY2Yhsm3CfRh2uT_QrkM3oqeFD_vgd9BnEjukDblt2EOPcWSbj-8XbA_OhUiMy8-3DKJnrxbz8oo-FRsS-z0Tzx8XDzsi4ZO7_0Xx6c3r2-t3s5sPb5fXi5uZK-t2nHlQTSc7rLrOcuAeOs21bmruEbD1XEvgqDVyKyWIunHaSm21wsZaqG2jLorlxPUDrA09egPpYAYI5udgSCsDaQyuRyM4lFxWJVKqZdURUmtKXGgtWxDWEktNrF3cwuEb9P09UHBzLMeszbEccyzHTOWQ63JybdPwdYd5NJuQHfY9RKSIjaLThFJVzUn67E66sxv09_RfxZFATgKXhpwTdv93gZeTCSnnfcBksgsYHfpAPY4URPi7_cUfdteHGBz0X_DwL_MPz-TRvg |
Cites_doi | 10.1038/s41598-023-46800-x 10.1126/science.abq1841 10.1371/journal.pone.0249499 10.3389/fimmu.2023.1100263 10.1056/NEJMc2213907 10.1038/s41385-022-00511-0 10.1038/s41586-021-04389-z 10.1038/s41467-024-47429-8 |
ContentType | Journal Article |
Copyright | 2024 The Author(s) Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
Copyright_xml | – notice: 2024 The Author(s) – notice: Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
CorporateAuthor | PRIBIVAC Cohort Study Group |
CorporateAuthor_xml | – name: PRIBIVAC Cohort Study Group |
DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY DOA |
DOI | 10.1016/j.ijid.2024.107147 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Public Health |
EISSN | 1878-3511 |
ExternalDocumentID | oai_doaj_org_article_10a40254e10745f0b29910119928a1bb 10.1016/j.ijid.2024.107147 38945433 10_1016_j_ijid_2024_107147 S1201971224002182 |
Genre | Journal Article |
GroupedDBID | --- --K .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 29J 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 7X7 88E 8C1 8FI 8FJ 8FQ 8R4 8R5 AAEDW AAFWJ AAIKJ AALRI AAQFI AAQXK AARKO AAXUO AAYWO ABBQC ABFRF ABMAC ABUWG ABWVN ACGFO ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFJKZ AFKRA AFPKN AFPUW AFRHN AFTJW AGEKW AGHFR AGQPQ AGYEJ AHMBA AIGII AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN BAWUL BCNDV BENPR BPHCQ BR6 BVXVI CCPQU CS3 DIK DU5 DWQXO E3Z EBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FNPLU FYUFA G-Q GBLVA GROUPED_DOAJ GX1 HMCUK HVGLF HZ~ IHE IXB J1W KQ8 M1P M3C M3G M41 MO0 N9A O-L O9- OD- OK1 OO. OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q2X Q38 QTD R2- ROL RPZ RWL RXW SDF SDG SEL SES SEW SSZ TAE UKHRP UNMZH Z5R 0SF 3V. 6I. AACTN AAFTH ABVKL AFCTW ALIPV NCXOZ RIG AAYXX CITATION ~HD CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY |
ID | FETCH-LOGICAL-c468t-da37f2fe5ffb0a0daf9099760deae8d092a0e99e0b22a167c9b29b93e7bba6b73 |
IEDL.DBID | DOA |
ISSN | 1201-9712 1878-3511 |
IngestDate | Wed Aug 27 01:31:16 EDT 2025 Wed Aug 20 00:16:01 EDT 2025 Mon Sep 29 03:52:56 EDT 2025 Mon Jul 21 05:55:51 EDT 2025 Wed Oct 01 05:07:40 EDT 2025 Sat Aug 10 15:31:11 EDT 2024 Tue Aug 26 18:38:49 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Bivalent Variant EG.5.1 SARS-CoV-2 IgA mRNA vaccine |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c468t-da37f2fe5ffb0a0daf9099760deae8d092a0e99e0b22a167c9b29b93e7bba6b73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-5407-0280 0000-0003-0349-1557 0000-0001-6077-0515 0000-0002-1763-913X 0000-0003-0813-9640 0000-0003-4978-5825 0000-0002-8797-9527 0000-0002-3112-7341 0000-0002-6110-7472 |
OpenAccessLink | https://doaj.org/article/10a40254e10745f0b29910119928a1bb |
PMID | 38945433 |
PQID | 3074133560 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_10a40254e10745f0b29910119928a1bb unpaywall_primary_10_1016_j_ijid_2024_107147 proquest_miscellaneous_3074133560 pubmed_primary_38945433 crossref_primary_10_1016_j_ijid_2024_107147 elsevier_sciencedirect_doi_10_1016_j_ijid_2024_107147 elsevier_clinicalkey_doi_10_1016_j_ijid_2024_107147 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | September 2024 2024-09-00 2024-Sep 20240901 2024-09-01 |
PublicationDateYYYYMMDD | 2024-09-01 |
PublicationDate_xml | – month: 09 year: 2024 text: September 2024 |
PublicationDecade | 2020 |
PublicationPlace | Canada |
PublicationPlace_xml | – name: Canada |
PublicationTitle | International journal of infectious diseases |
PublicationTitleAlternate | Int J Infect Dis |
PublicationYear | 2024 |
Publisher | Elsevier Ltd Elsevier |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
References | Urschel, Bronder, Klemis, Marx, Hielscher, Abu-Omar (bib0006) 2024; 15 Cao, Jian, Wang, Yu, Song, Yisimayi (bib0004) 2023; 614 Reynolds, Pade, Gibbons, Otter, Lin, Munoz Sandoval (bib0005) 2022; 377 Goh, Chavatte, Lim Jieling, Lee, Hor, Amrun (bib0002) 2021; 2 Liew, Kua, Lee, Wong (bib0008) 2023; 14 Goh, Fong, Tay, Rouers, Chang, Chavatte (bib0010) 2023; 13 Sheikh-Mohamed, Isho, Chao, Zuo, Cohen, Lustig (bib0009) 2022; 15 Wisnewski, Campillo Luna, Redlich (bib0007) 2021; 16 Planas, Saunders, Maes, Guivel-Benhassine, Planchais, Buchrieser (bib0001) 2022; 602 Wang, Bowen, Valdez, Gherasim, Gordon, Liu (bib0003) 2023; 388 Goh (10.1016/j.ijid.2024.107147_bib0010) 2023; 13 Goh (10.1016/j.ijid.2024.107147_bib0002) 2021; 2 Sheikh-Mohamed (10.1016/j.ijid.2024.107147_bib0009) 2022; 15 Urschel (10.1016/j.ijid.2024.107147_bib0006) 2024; 15 Wisnewski (10.1016/j.ijid.2024.107147_bib0007) 2021; 16 Cao (10.1016/j.ijid.2024.107147_bib0004) 2023; 614 Planas (10.1016/j.ijid.2024.107147_bib0001) 2022; 602 Wang (10.1016/j.ijid.2024.107147_bib0003) 2023; 388 Reynolds (10.1016/j.ijid.2024.107147_bib0005) 2022; 377 Liew (10.1016/j.ijid.2024.107147_bib0008) 2023; 14 |
References_xml | – volume: 13 start-page: 19331 year: 2023 ident: bib0010 article-title: Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave publication-title: Sci Rep – volume: 2 year: 2021 ident: bib0002 article-title: Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19 publication-title: Cell Rep Med – volume: 15 start-page: 3077 year: 2024 ident: bib0006 article-title: SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals publication-title: Nat Commun – volume: 602 start-page: 671 year: 2022 end-page: 675 ident: bib0001 article-title: Considerable escape of SARS-CoV-2 Omicron to antibody neutralization publication-title: Nature – volume: 377 start-page: eabq1841 year: 2022 ident: bib0005 article-title: Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure publication-title: Science – volume: 388 start-page: 567 year: 2023 end-page: 569 ident: bib0003 article-title: Antibody response to Omicron BA.4-BA.5 bivalent booster publication-title: N Engl J Med – volume: 14 year: 2023 ident: bib0008 article-title: SARS-CoV-2 neutralizing antibody bebtelovimab—a systematic scoping review and meta-analysis publication-title: Front Immunol – volume: 15 start-page: 799 year: 2022 end-page: 808 ident: bib0009 article-title: Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection publication-title: Mucosal Immunol – volume: 16 year: 2021 ident: bib0007 article-title: Human IgG and IgA responses to COVID-19 mRNA vaccines publication-title: PLoS One – volume: 614 start-page: 521 year: 2023 end-page: 529 ident: bib0004 article-title: Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution publication-title: Nature – volume: 13 start-page: 19331 year: 2023 ident: 10.1016/j.ijid.2024.107147_bib0010 article-title: Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave publication-title: Sci Rep doi: 10.1038/s41598-023-46800-x – volume: 614 start-page: 521 issue: 7948 year: 2023 ident: 10.1016/j.ijid.2024.107147_bib0004 article-title: Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution publication-title: Nature – volume: 2 issue: 2 year: 2021 ident: 10.1016/j.ijid.2024.107147_bib0002 article-title: Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19 publication-title: Cell Rep Med – volume: 377 start-page: eabq1841 issue: 6603 year: 2022 ident: 10.1016/j.ijid.2024.107147_bib0005 article-title: Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure publication-title: Science doi: 10.1126/science.abq1841 – volume: 16 issue: 6 year: 2021 ident: 10.1016/j.ijid.2024.107147_bib0007 article-title: Human IgG and IgA responses to COVID-19 mRNA vaccines publication-title: PLoS One doi: 10.1371/journal.pone.0249499 – volume: 14 year: 2023 ident: 10.1016/j.ijid.2024.107147_bib0008 article-title: SARS-CoV-2 neutralizing antibody bebtelovimab—a systematic scoping review and meta-analysis publication-title: Front Immunol doi: 10.3389/fimmu.2023.1100263 – volume: 388 start-page: 567 issue: 6 year: 2023 ident: 10.1016/j.ijid.2024.107147_bib0003 article-title: Antibody response to Omicron BA.4-BA.5 bivalent booster publication-title: N Engl J Med doi: 10.1056/NEJMc2213907 – volume: 15 start-page: 799 issue: 5 year: 2022 ident: 10.1016/j.ijid.2024.107147_bib0009 article-title: Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection publication-title: Mucosal Immunol doi: 10.1038/s41385-022-00511-0 – volume: 602 start-page: 671 issue: 7898 year: 2022 ident: 10.1016/j.ijid.2024.107147_bib0001 article-title: Considerable escape of SARS-CoV-2 Omicron to antibody neutralization publication-title: Nature doi: 10.1038/s41586-021-04389-z – volume: 15 start-page: 3077 issue: 1 year: 2024 ident: 10.1016/j.ijid.2024.107147_bib0006 article-title: SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals publication-title: Nat Commun doi: 10.1038/s41467-024-47429-8 |
SSID | ssj0004668 |
Score | 2.394046 |
Snippet | •Immune escape of SARS-CoV-2 variants spurred the development of bivalent vaccines.•We compared antibody response following monovalent or bivalent mRNA... The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent... Objectives: The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how... |
SourceID | doaj unpaywall proquest pubmed crossref elsevier |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 107147 |
SubjectTerms | Adult Aged Antibodies, Viral - blood Bivalent COVID-19 - immunology COVID-19 - prevention & control COVID-19 - virology COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology EG.5.1 Female Humans IgA Immunization, Secondary Immunoglobulin A - blood Male Middle Aged mRNA vaccine mRNA Vaccines SARS-CoV-2 SARS-CoV-2 - genetics SARS-CoV-2 - immunology Spike Glycoprotein, Coronavirus - genetics Spike Glycoprotein, Coronavirus - immunology Vaccination Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - immunology Variant Young Adult |
SummonAdditionalLinks | – databaseName: ScienceDirect dbid: IXB link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VPfBQhaC8wktG4gCCsEnsPHzcragKUnuAVuwtshO7crUkq30U9cg_ZyZOlq2QAHGJFGuSOJnJzNj-vjHAK1kLDAK2CmVtMxygpEWoqpxGKYYXiTRS18RGPj7Jjs7Ep2k63YGDgQtDsMre93uf3nnrvmXUf83R3LnRlxhjl8zjDgVJdcjRD3ORdyS-6WSLG-npcCgcknRPnPEYL3fhqFpoIrAhj2mLla3g1NXwvxajfs9Bb8PNdTNXV9_VbLYVlw7vwp0-oWRj3-d7sGOafbhx3C-Z78Oen5hjnm90H37QNILr9odgrWUfz8ds4XGyZslcw-aE-23Xy9kV80AtUzO3YW0tUbgyjmYhmHZopRiz2LfPJ2N2qSp64JK9_nrKVFOzyfi9GOEhZe2C_WqL3zyAs8MPpwdHYb8PQ1iJrFiFteK5TaxJrdWRimplJfFts6g2yhR1JBMVGSlNpJNExVleSZ1ILbnJtVaZzvlD2G3axjwGZmSGt-JGChwJKR4VWsdFpbXUuVQ2iQN4OyignPtyG-WAQ7soSV0lqav06gpgQjraSFKp7K6hXZyXva2gqBJE-TcEPU0tdhJTYqp0J5NCxVoHwAcNlwMbFf0n3sj98dHp5qpr9vrX614ORlTij0yrM6oxqNWSU3LHOWagATzy1rV5McwqRSo4D-Ddxtz-4fs8-c9OPoVbdOahdM9gd7VYm-eYe630i-7n-gmQqib- priority: 102 providerName: Elsevier |
Title | Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1) |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1201971224002182 https://dx.doi.org/10.1016/j.ijid.2024.107147 https://www.ncbi.nlm.nih.gov/pubmed/38945433 https://www.proquest.com/docview/3074133560 https://doi.org/10.1016/j.ijid.2024.107147 https://doaj.org/article/10a40254e10745f0b29910119928a1bb |
UnpaywallVersion | publishedVersion |
Volume | 146 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1878-3511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004668 issn: 1201-9712 databaseCode: KQ8 dateStart: 19960101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1878-3511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004668 issn: 1201-9712 databaseCode: KQ8 dateStart: 19960701 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1878-3511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004668 issn: 1201-9712 databaseCode: DOA dateStart: 19960101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1878-3511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004668 issn: 1201-9712 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1878-3511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004668 issn: 1201-9712 databaseCode: .~1 dateStart: 19960701 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect customDbUrl: eissn: 1878-3511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004668 issn: 1201-9712 databaseCode: IXB dateStart: 19960701 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1878-3511 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0004668 issn: 1201-9712 databaseCode: DIK dateStart: 19960101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1878-3511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004668 issn: 1201-9712 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1878-3511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004668 issn: 1201-9712 databaseCode: AKRWK dateStart: 19960701 isFulltext: true providerName: Library Specific Holdings |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BDzyEEJRXeFRG4gCClCR2Hj7uIqoWqT2gVuzNsmMbpVqyq32AekHinzOzTsIiJMqBiw-WH4m_sWdszzcGeCGtQCXg61haX-AGJa9iXZe0S3G8yqSTxhIb-fikODwTHyb5ZOupL_IJC-GBw8DhrNaCGNuOPAdznxhcP1MKVCazSqfG0OqLaqzfTA2MyECCQ_UWyzLNOrpM8OxqzhuKEZoJzChTelhlSyVtIvf_ppn-tDxvwvV1O9cX3_R0uqWNDu7A7c6MZKPw-Xfhimt34dpxd1G-C7fCcRwLLKN78IMOD5rNqxBs5tnR5xFbBO9Yt2RNy-bk7TtbL6cXLLhnOcuagau1xMK1a-jsgZkGZRM1Ffvy8WTEvuqaOlyyl59OmW4tG4_2xVtMcjZbsF956av7cHbw_vTdYdy9vhDXoqhWsdW89Jl3ufcm0YnVXhLLtkis066yicx04qR0iEim06KsJUJjJHelMbowJX8AO-2sdY-AOVlgU9xJgfsfzZPKmLSqjZGmlNpnaQSvewDUPATZUL332bkiuBTBpQJcEYwJo6EkBcjeZKDYqE5s1GViEwHvEVY9BxVXTWyo-WvX-VCrs1CC5XFpvee9ECmcvnQno1uHqCpOJh3naHdG8DBI1_BjaEuKXHAewZtB3P5hfB7_j_F5AjeoyeBN9xR2Vou1e4bm18rswdX97-neZr5hejQZ_wRsCSbg |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlEQQlBe4WkkDiBIN4nz8nFbUW2huwfYit4sO3GqVEuy2geoFyT-OTNxErZCAsQlB2fiOJmxZ2x_3xjgpchDdAJF5oq8iHGCEqWuyhKapRieBsIInRMbeTyJRyfh-9PodAsOOi4MwSrbsd-O6c1o3ZYM2r85mJfl4JOPvkskfoOCpDzkV-BqSBaFRr333d8gR1o-HEq7JN4yZyzIqzwvKV1oEGJB4tMZKxveqUnif8lJ_R6E3oCddTVXF9_UbLbhmA5vw602omRD2-g7sGWqXbg2bvfMd-GmXZljlnB0F37QOkLZHBDB6oIdnQ3ZwgJlzZKVFZsT8LdeL2cXzCK1TM7Knra1ROHMlLQMwXSJZopOi335OBmyryqjFy7Zq89Tpqqc7Q_3wgFeIlYv2K8y__U9ODl8Nz0Yue1BDG4WxunKzRVPiqAwUVFoT3m5KgQRbmMvN8qkuScC5RkhjKeDQPlxkgkdCC24SbRWsU74fdiu6so8BGZEjFVxI0KcCinupVr7aaa10IlQReA78KZTgJzbfBuyA6KdS1KXJHVJqy4H9klHvSTlym4K6sWZbI0FRVVInH9D2NOowEZiTEyp7kSQKl9rB3inYdnRUXEAxYrKP7466p-6ZLB_fe5FZ0QSezJtz6jKoFYlp-iOcwxBHXhgrav_MAwrwyjk3IG3vbn9w_959J-NfA47o-n4WB4fTT48hut0x-LqnsD2arE2TzEQW-lnTUf7CU4nKhI |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Imprinting+of+IgA+responses+in+previously+infected+individuals+receiving+bivalent+mRNA+vaccines+%28WT+and+BA.4%2FBA.5+or+WT+and+BA.1%29&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Goh%2C+Yun+Shan&rft.au=Fong%2C+Siew-Wai&rft.au=Hor%2C+Pei+Xiang&rft.au=Loh%2C+Chiew+Yee&rft.date=2024-09-01&rft.eissn=1878-3511&rft.volume=146&rft.spage=107147&rft_id=info:doi/10.1016%2Fj.ijid.2024.107147&rft_id=info%3Apmid%2F38945433&rft.externalDocID=38945433 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon |